Foghorn Therapeutics Inc. announced on April 28, 2025, the presentation of new preclinical data for its potential first-in-class medicines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The data highlighted synergistic anti-tumor activity of FHD-909, a SMARCA2 selective inhibitor, in combination with standard-of-care chemotherapies, anti-PD-1 pembrolizumab, and KRAS inhibitors in NSCLC animal models.
For its Selective CBP degrader program, initial preclinical data demonstrated combinatorial benefit with approved chemotherapies and targeted agents in solid tumors, including ER+ breast cancer models, suggesting potential beyond EP300-mutant cancers. A potent and selective heterobifunctional degrader of EP300 also showed significant preclinical activity in hematological malignancies.
The company also provided an overview of its Selective ARID1B degrader program, identifying it as a major synthetic lethal target implicated in up to 5% of all solid tumors. Enrollment and dose escalation are continuing in the ongoing Phase 1 trial evaluating FHD-909 in patients with SMARCA4 mutations who have exhausted standard treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.